Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03897881
Title An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Patients With High-Risk Melanoma (KEYNOTE-942)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors ModernaTX, Inc.

skin melanoma


mRNA-4157 + Pembrolizumab


Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.